Clinical-stage biotechnology company Attovia Therapeutics has significantly expanded its planned initial public offering, increasing the size of the deal by 45% as investor demand strengthens ahead of its anticipated Nasdaq debut.
The San Carlos, California-based company now plans to raise approximately $289 million by offering 17 million shares at a proposed price of $17 per share. The revised terms represent a substantial increase from its previous filing, which called for the sale of 12.5 million shares at a price range of $15 to $17.
At the updated pricing, Attovia Therapeutics is expected to achieve a fully diluted market valuation of approximately $767 million. The company remains on track to price its IPO during the week of August 3, 2026, and intends to trade on the Nasdaq under the ticker symbol ATTO.
Strong Investor Interest Supports Larger Offering
The decision to increase both the number of shares offered and set the proposed price at the top of the previously indicated range suggests robust institutional demand during the company’s IPO marketing process.
If completed at the revised terms, Attovia will raise approximately 45% more capital than originally anticipated, providing additional financial resources to accelerate the development of its clinical pipeline and platform technology.
The expanded offering also reflects continued investor appetite for biotechnology companies developing innovative treatments for immune-mediated diseases, a therapeutic area that has attracted significant investment in recent years.
Proprietary ATTOBODY Platform Targets Immune Disorders
Founded in 2022, Attovia Therapeutics is developing biologic therapies for immune-mediated diseases using its proprietary ATTOBODY platform, a biparatopic nanobody technology licensed from Alamar Biosciences.
The platform is designed to engineer highly targeted biologic medicines capable of addressing complex inflammatory diseases by engaging multiple biological pathways simultaneously. The technology aims to improve efficacy while potentially offering differentiated therapeutic profiles compared with conventional antibody treatments.
Lead Candidate Advances Through Clinical Development
Attovia’s lead investigational therapy, ATTO-1310, targets interleukin-31 (IL-31), a cytokine associated with chronic itching and inflammatory skin disorders.
The candidate has completed Phase 1 dosing in both healthy volunteers and patients with chronic pruritus and atopic dermatitis, positioning it as the company’s most advanced clinical program.
Beyond its lead asset, Attovia continues advancing two additional pipeline candidates.
ATTO-2306 is a bispecific biologic targeting IL-13 and IL-31 for the treatment of atopic dermatitis and related inflammatory skin diseases. The program is currently completing IND-enabling studies, with a Phase 1 clinical trial expected during the first half of 2027.
The company’s third program, ATTO-1091, is a trispecific biologic targeting TL1A, IL-23, and integrin α4β7 for inflammatory bowel disease. This candidate also remains in IND-enabling development.
Early-Stage Company Focused on Pipeline Expansion
Like many emerging biotechnology companies, Attovia remains in the clinical development stage and has no approved commercial products.
For the 12 months ended March 31, 2026, the company reported approximately $1 million in revenue, reflecting its early-stage operating profile. Proceeds from the IPO are expected to support continued clinical trials, research and development, regulatory activities, manufacturing scale-up, and general corporate purposes.
The offering is being led by a syndicate of investment banks including Morgan Stanley, Leerink Partners, Citi, RBC Capital Markets, and LifeSci Capital.
Outlook
Attovia Therapeutics enters the public markets at a time when investor interest in innovative immunology and inflammatory disease therapies remains strong. The decision to expand the offering by 45% suggests growing confidence in the company’s proprietary ATTOBODY platform and its pipeline of biologic candidates targeting dermatological and gastrointestinal immune disorders. While Attovia remains an early-stage clinical developer with no commercial products, the larger capital raise provides additional financial flexibility to advance multiple programs as it pursues long-term growth in the competitive biotechnology sector.
